Alembic Global Sticks to Its Buy Rating for Celanese (CE)
Alembic Global analyst Hassan Ahmed maintained a Buy rating on Celanese (CE – Research Report) today and set a price target of $70.00. The company's shares closed today at $44.77.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Ahmed covers the Basic Materials sector, focusing on stocks such as Air Products and Chemicals, Celanese, and TRONOX. According to TipRanks, Ahmed has an average return of 3.0% and a 45.25% success rate on recommended stocks.
Celanese has an analyst consensus of Hold, with a price target consensus of $59.00.
Based on Celanese's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.37 billion and a GAAP net loss of $1.91 billion. In comparison, last year the company earned a revenue of $2.57 billion and had a net profit of $698 million
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CE in relation to earlier this year. Most recently, in March 2025, Ganesh Moorthy, a Director at CE bought 1,000.00 shares for a total of $53,280.00.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
Stifel Nicolaus Sticks to Their Buy Rating for Alkermes (ALKS)
In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Alkermes (ALKS – Research Report), with a price target of $42.00. The company's shares closed last Friday at $29.09. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Matteis is a 3-star analyst with an average return of 1.2% and a 41.20% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Alkermes, Neurocrine, and uniQure. In addition to Stifel Nicolaus, Alkermes also received a Buy from UBS's Ashwani Verma in a report issued on June 17. However, on June 10, RBC Capital maintained a Hold rating on Alkermes (NASDAQ: ALKS).
Business Insider
2 hours ago
- Business Insider
Ventyx Biosciences (VTYX) Gets a Hold from Stifel Nicolaus
In a report released today, from Stifel Nicolaus maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report), with a price target of $2.00. The company's shares closed last Friday at $2.26. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter In addition to Stifel Nicolaus, Ventyx Biosciences also received a Hold from Morgan Stanley's Vikram Purohit in a report issued on June 17. However, on June 18, Wells Fargo maintained a Buy rating on Ventyx Biosciences (NASDAQ: VTYX). VTYX market cap is currently $160.8M and has a P/E ratio of -1.29.
Business Insider
2 hours ago
- Business Insider
Stifel Nicolaus Keeps Their Buy Rating on Dianthus Therapeutics (DNTH)
In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Dianthus Therapeutics (DNTH – Research Report), with a price target of $52.00. The company's shares closed last Friday at $16.86. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Thompson CFA covers the Healthcare sector, focusing on stocks such as Kymera Therapeutics, Travere Therapeutics, and Viridian Therapeutics. According to TipRanks, Thompson CFA has an average return of -3.4% and a 43.20% success rate on recommended stocks. Dianthus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $46.75, which is a 177.37% upside from current levels. In a report released on June 18, LifeSci Capital also maintained a Buy rating on the stock with a $45.00 price target. The company has a one-year high of $32.27 and a one-year low of $13.37. Currently, Dianthus Therapeutics has an average volume of 319.1K.
